EarlyCDT-Lung
The EarlyCDT® Lung test detects the presence of autoantibodies generated by the body’s immune system, a natural defense against cancer cells. This aids in the early detection of lung cancer in high-risk patients.
Leading Precision Medicine In South East Asia (Sea)
Pathomics Health focuses on advanced precision medicine diagnostics and digital healthcare solutions to provide patients access to better outcome.
Leading Precision Medicine In South East Asia (Sea)
Pathomics Health focuses on advanced precision medicine diagnostics and digital healthcare solutions to provide patients access to better outcome.
Our Mission
Advancing Diagnostics & Digital Health Solutions for Better Health
We focus on advanced precision medicine diagnostics and digital healthcare solutions.
Our Vision
Universal Accessibility to Affordable Precision Diagnostics & Screening
We offer an innovative, scalable and cost-effective advanced diagnostics platform, combining with cutting-edge technology and design to help patients and individuals to improve their health.
Our Commitment
We are committed in delivering high-quality and yet affordable diagnostics solutions to meet the diverse needs of our customers. Contact us today to find out more about our service offerings.
Company Milestones - Driving Excellence Since 2017
2022
-
Nov 2022
Clinical Laboratory Obtains MOH License in Singapore
-
Aug 2022
MAHSA Health Collaboration
-
Aug 2022
Pacific Insurance Collaboration
-
Aug 2022
MiCare Collaboration
-
Feb 2022
Official Opening of Laboratory in Singapore
2017
-
Nov 2017
Launching of GEMS@UM Laboratory
Our Laboratories
Investor Relations
Pathomics Health takes a proactive approach in managing its Investor Relations to cultivate strong relationships and effective communication with its investors. This involves regular engagement with stakeholders to foster trust and provide timely updates on financial performance, market conditions, and strategic initiatives. Through transparent and consistent communication, the company aims to enhance investor understanding, confidence, and engagement.